Pricing Log in Create free account

AgomAb Therapeutics NV (AGMB) vs Contineum Therapeutics, Inc. (CTNM)

AgomAb Therapeutics NV and Contineum Therapeutics, Inc. are both Biotechnology companies. AgomAb Therapeutics NV and Contineum Therapeutics, Inc. are of similar size ($345.9M and $343.3M). Across the 6 metrics below, AgomAb Therapeutics NV leads on 3 and Contineum Therapeutics, Inc. on 3.

Valuation

Metric AGMB CTNM Biotechnology median
P/E — n/m 10.60
P/S — n/m 9.40
P/B n/m 1.47 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m n/m 9.02
Earnings yield — (18.76%) (32.88%)
Free cash flow yield 0.00% (14.44%) (23.13%)

Profitability

Metric AGMB CTNM Biotechnology median
Gross margin — — 68.51%
Operating margin — 0.00% 0.00%
Net margin — 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity — (29.80%) (51.96%)
Return on assets — (28.34%) (46.06%)
Return on invested capital 0.00% (4,845.62%) 0.00%

Growth

Metric AGMB CTNM Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (39.80%) 0.46% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric AGMB CTNM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.88 31.11 4.97
Net debt to EBITDA 1.96 3.88 1.01

Dividend

Metric AGMB CTNM Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AGMB CTNM Biotechnology median
Market cap 343.27m 345.93m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack